Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2992526 | 1.00 | USP2 (0.40) | USP2 | |
| SCHEMBL17925008 | 0.91 | — | — | |
| SCHEMBL2605896 | 0.89 | HSD17B10 (0.30) | — | |
| SCHEMBL6973518 | 0.82 | LMNA (0.36) | USP2 | |
| SCHEMBL6973523 | 0.82 | LMNA (0.36) | USP2 | |
| SCHEMBL5350628 | 0.82 | LMNA (0.36) | USP2 | |
| SCHEMBL5351265 | 0.82 | LMNA (0.36) | USP2 | |
| SCHEMBL3386278 | 0.81 | HIF1A (0.33) | — | |
| SCHEMBL30916829 | 0.78 | HSD17B10 (0.41) | — | |
| SCHEMBL30916813 | 0.78 | HSD17B10 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032669-B | Orthoester compositions for affinity purification of oligonucleotides | 安捷伦科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230322742-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322742-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230122968-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11548876-B2 | Orthoester compositions for affinity purification of oligonucleotides | AGILENT TECHNOLOGIES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11299483-B2 | Orthoester compositions for affinity purification of oligonucleotides | AGILENT TECHNOLOGIES, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3668883-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | Agilent Technologies, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20200190129-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200181124-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES, INC. | 2020-06-11 | — | — | US | disclosed |
| EP-2744024-B1 | METHOD FOR PRODUCING ELECTRODE CATALYST FOR FUEL CELLS | SHOWA DENKO KK (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-20150093681-A1 | METHOD FOR PRODUCING FUEL CELL ELECTRODE CATALYST, FUEL CELL ELECTRODE CATALYST, AND USES THEREOF | SHOWA DENKO K.K. (JP) | 2015-04-02 | — | — | US | disclosed |
| US-20140170528-A1 | PROCESS FOR PRODUCING A FUEL CELL ELECTRODE CATALYST, FUEL CELL ELECTRODE CATALYST AND USE THEREOF | SHOWA DENKO K.K. (JP) | 2014-06-19 | — | — | US | disclosed |
| EP-2744024-A1 | METHOD FOR PRODUCING ELECTRODE CATALYST FOR FUEL CELLS, ELECTRODE CATALYST FOR FUEL CELLS, AND USE OF SAME | Showa Denko K.K. (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-7662481-B2 | Endless belt for electrophotographic apparatus | TOKAI RUBBER INDUSTRIES, LTD. (JP) | 2010-02-16 | — | — | US | disclosed |
| US-7465480-B2 | Polymer/cholesteric liquid crystal dispersion, method of producing the same liquid crystal display element using the same | FUJI XEROX CO., LTD. (JP) | 2008-12-16 | — | — | US | disclosed |
| US-20050244590-A1 | Polymer/cholesteric liquid crystal dispersion, method of producing the same and liquid crystal display element using the same | FUJI XEROX CO., LTD. | 2005-11-03 | — | — | US | disclosed |
| US-20050196202-A1 | Endless belt for electrophotographic apparatus | TOKAI RUBBER INDUSTRIES, LTD. (JP) | 2005-09-08 | — | — | US | disclosed |
| EP-0736809-B1 | Composition for anti-reflective coating on resist | MITSUBISHI CHEM CORP (JP) | 2000-10-11 | — | — | EP | disclosed |
| US-5611850-A | FLUORO COMPOUND | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-03-18 | — | — | US | disclosed |
| EP-0736809-A1 | Composition for anti-reflective coating on resist | Mitsubishi Chemical Corporation (JP) | 1996-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190129-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | RNGTT, OSBPL8, DCLRE1B | USP2 959/4885 |
| US-20230122968-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | RNGTT, DCLRE1B, MRTO4 | USP2 816/4885 |
| US-20200181124-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | RNGTT, OSBPL8, DCLRE1B | USP2 959/4885 |
| US-11548876-B2 | Orthoester compositions for affinity purification of oligonucleotides | RNGTT, OSBPL8, DCLRE1B | USP2 959/4885 |
| US-20230322742-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | RNGTT, OSBPL8, DCLRE1B | USP2 959/4885 |
| US-11299483-B2 | Orthoester compositions for affinity purification of oligonucleotides | RNGTT, OSBPL8, DCLRE1B | USP2 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.